SIGN THERPAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.25 USD | +5.00% |
|
+5.00% | +10.99% |
| Feb. 20 | Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 43.76 | 18.65 | 6.34 | 6.077 |
| Enterprise Value (EV) 1 | 44.19 | 19.24 | 8.209 | 8.543 |
| P/E ratio | -7.47 x | -6.06 x | -2.13 x | -1.25 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -48.8 x | -7.62 x | -3.84 x | -3.49 x |
| EV / FCF | - | -27,071,209 x | -11,224,245 x | 27,818,311 x |
| FCF Yield | - | -0% | -0% | 0% |
| Price to Book | 454 x | -70.5 x | -3.42 x | -1.79 x |
| Nbr of stocks (in thousands) | 855 | 932 | 932 | 1,285 |
| Reference price 2 | 51.20 | 20.00 | 6.800 | 4.730 |
| Announcement Date | 4/6/21 | 3/21/22 | 3/31/23 | 2/20/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA | - | -0.9051 | -2.525 | -2.137 | -2.446 |
| EBIT 1 | -0.0093 | -0.9164 | -2.544 | -2.147 | -2.455 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.0093 | -1.26 | -3.005 | -2.93 | -4.146 |
| Net income 1 | -0.0093 | -1.26 | -3.005 | -2.93 | -4.146 |
| Net margin | - | - | - | - | - |
| EPS | - | -6.854 | -3.302 | -3.200 | -3.770 |
| Free Cash Flow | - | - | -0.7108 | -0.7314 | 0.3071 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/6/21 | 4/6/21 | 3/21/22 | 3/31/23 | 2/20/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt | - | 0.43 | 0.59 | 1.87 | 2.47 |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.4798 x | -0.2348 x | -0.8746 x | -1.008 x |
| Free Cash Flow | - | - | -0.71 | -0.73 | 0.31 |
| ROE (net income / shareholders' equity) | - | -2,564% | 3,633% | 270% | 156% |
| ROA (Net income/ Total Assets) | - | - | -226% | -257% | -469% |
| Assets 1 | - | - | 1.327 | 1.139 | 0.8844 |
| Book Value Per Share | - | 0.1100 | -0.2800 | -1.990 | -2.650 |
| Cash Flow per Share | - | 0.1000 | 0.3700 | 0.0100 | 0.0100 |
| Capex | - | - | 0.03 | 0 | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/6/21 | 4/6/21 | 3/21/22 | 3/31/23 | 2/20/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
- Stock Market
- Equities
- SIGY Stock
- Financials SIGN THERPAR